SLC7A11 and neoplasm: Several studies have shown that PRIMA-1Met treatment leads to an increase in SLC7A11/xCT protein, known to promote glutathione synthesis, contributing to the maintenance of the redox balance in tumor cells carrying mutant p53 [23,32,33].